Last reviewed · How we verify

Fluticasone/Salmeterol Discus 500/50 µg

AstraZeneca · Phase 3 active Small molecule

Fluticasone/Salmeterol Discus 500/50 µg is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.

Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameFluticasone/Salmeterol Discus 500/50 µg
SponsorAstraZeneca
Drug classInhaled corticosteroid/long-acting beta-2 agonist combination
TargetGlucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and sustained airway opening. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fluticasone/Salmeterol Discus 500/50 µg

What is Fluticasone/Salmeterol Discus 500/50 µg?

Fluticasone/Salmeterol Discus 500/50 µg is a Inhaled corticosteroid/long-acting beta-2 agonist combination drug developed by AstraZeneca, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Fluticasone/Salmeterol Discus 500/50 µg work?

Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.

What is Fluticasone/Salmeterol Discus 500/50 µg used for?

Fluticasone/Salmeterol Discus 500/50 µg is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Fluticasone/Salmeterol Discus 500/50 µg?

Fluticasone/Salmeterol Discus 500/50 µg is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is Fluticasone/Salmeterol Discus 500/50 µg in?

Fluticasone/Salmeterol Discus 500/50 µg belongs to the Inhaled corticosteroid/long-acting beta-2 agonist combination class. See all Inhaled corticosteroid/long-acting beta-2 agonist combination drugs at /class/inhaled-corticosteroid-long-acting-beta-2-agonist-combination.

What development phase is Fluticasone/Salmeterol Discus 500/50 µg in?

Fluticasone/Salmeterol Discus 500/50 µg is in Phase 3.

What are the side effects of Fluticasone/Salmeterol Discus 500/50 µg?

Common side effects of Fluticasone/Salmeterol Discus 500/50 µg include Tremor, Headache, Palpitations, Muscle cramps, Oral candidiasis, Hoarseness.

What does Fluticasone/Salmeterol Discus 500/50 µg target?

Fluticasone/Salmeterol Discus 500/50 µg targets Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) and is a Inhaled corticosteroid/long-acting beta-2 agonist combination.

Related